Detecting septin-5 IgG by cell-binding assay using cerebrospinal fluid specimens
If the indirect immunofluorescence (IFA) pattern suggests septin-5, then this test and septin-5 antibody IFA titer will be performed at an additional charge.
Only orderable as a reflex. For more information see MDC2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid.
Cell-Binding Assay (CBA)
CDCREL
CDCREL-1
CDCREL1
H5
HCDCREL-1
PNUTL1
septin 5
SEPT5
If the indirect immunofluorescence (IFA) pattern suggests septin-5, then this test and septin-5 antibody IFA titer will be performed at an additional charge.
CSF
Only orderable as a reflex. For more information see MDC2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid.
Container/Tube: Sterile vial
Specimen Volume: 1.5 mL
See Specimen Required
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
CSF | Refrigerated (preferred) | 28 days | |
Frozen | 28 days | ||
Ambient | 72 hours |
Detecting septin-5 IgG by cell-binding assay using cerebrospinal fluid specimens
If the indirect immunofluorescence (IFA) pattern suggests septin-5, then this test and septin-5 antibody IFA titer will be performed at an additional charge.
Septin-5 IgG is a biomarker of a rapidly progressive, but treatable, form of autoimmune cerebellar ataxia. Patients present with subacute onset of cerebellar ataxia with prominent eye movement symptoms (oscillopsia or vertigo).
Improvement may occur after immunotherapy.
Only orderable as a reflex. For more information see MDC2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid.
Negative
Seropositivity for septin antibodies by indirect immunofluorescence (IFA) is consistent with a diagnosis of autoimmune disease of the central nervous system. Cell-binding assay (CBA) testing for septin-5 IgG is required to confirm the diagnosis. Seropositivity for septin-5 IgG by CBA confirms a diagnosis of autoimmune disease of the central nervous system.
Negative results for septin-5 IgG by cell-binding assay do not exclude neurological autoimmunity or cancer.
1. Honorat JA, Lopez-Chiriboga AS, Kryzer TJ, et al: Autoimmune septin-5 cerebellar ataxia. Neurol Neuroimmunol Neuroinflamm. 2018 Jul 9;5(5):e474
2. Honorat JA, Miske R, Scharf M, et al: 416. Neuronal septin autoimmunity: Differentiated serological profiles and clinical findings. Ann Neurol. 2020 Oct;88(Suppl 25):S55. Abstract
Patient specimen is applied to a composite slide containing transfected and nontransfected HEK-293 cells. After incubation and washing, fluorescein-conjugated goat-antihuman IgG is applied to detect the presence of patient IgG binding.(Package insert: IIFT: Neurology Mosaics, Instructions for the indirect immunofluorescence test. EUROIMMUN; FA_112d-1_A_UK_C13, 02/2019)
Monday through Sunday
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.
86255
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
SP5CC | Septin-5 CBA, CSF | In Process |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
615868 | Septin-5 CBA, CSF | In Process |